Hagar

About Hagar

Hagar N.I.G. is a Tel Aviv-based medical technology company established in 2017 with a focus on diabetes management. The company was co-founded by CEO Guy Zur, Chairman Bentzi Gruber, CTO Dr. Gerry Waintraub, and Director of Business Development Taire Rubin. The inspiration for the company's core technology came serendipitously when Dr. Waintraub, an expert with over 30 years in RF wave technology, observed that sugar from a spilled cup of tea caused a significant reaction on an RF device's monitors, sparking the idea for a non-invasive glucose measurement method.

Hagar is developing GWave, a non-invasive continuous glucose monitoring (CGM) system that utilizes radio frequency (RF) waves to measure glucose levels directly from the blood. This approach differs from existing CGM products that typically measure glucose in the interstitial fluid, which can introduce delays and inaccuracies in readings. The company targets the vast market of individuals with diabetes and pre-diabetes, offering a painless alternative to traditional finger-prick testing and invasive CGM devices. The business model appears to be centered on the development and eventual sale of this technology to a major medical technology firm for global distribution.

The primary product, GWave, sends real-time glucose readings to a smartphone application, allowing users and their healthcare providers to continuously track glucose levels. An automated alert system notifies users of significant fluctuations. The first-generation device is about one-third the size of a smartphone and emits less radiation. The ultimate goal is to integrate the GWave sensor into a smartwatch, making it a convenient and accessible consumer wellness product. The technology received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2021, and the company has been actively conducting clinical trials to validate its accuracy and prepare for market entry. To date, Hagar has successfully raised $25 million in funding through multiple rounds, including a $5 million Series C, to finance these trials and international patent applications.